RxDoctor Payments Data

Phillip Ahn, MD

Family Medicine · Chicago, ILNPI 1376527879

Payments from drug & device makers

$7,836in general payments, 2019–2025

Across 79 payments — averaging $99.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$3K
  • Johnson & Johnson$2K
  • Novo Nordisk$983
  • Merck$566
  • Chugai Pharmaceutical Co., Ltd.$422
  • Amgen$311
  • plus $528 from 6 others

What the payments were for

  • Consulting fees$3,47844%
  • Travel & lodging$1692%
  • Food & beverage$4,18953%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,836 in reported general payments places this provider in the 90th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$34,354
Medicare patients
59
Services billed
460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin14$23,098
OzempicSemaglutide20$21,836
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,783
Albuterol Sulfate HfaAlbuterol Sulfate49$1,701
Rosuvastatin Calcium54$771
Nifedipine ErNifedipine23$637
Levothyroxine Sodium40$607
Metoprolol Succinate46$461
Atorvastatin Calcium84$455
Fluticasone Propionate33$427
Losartan Potassium43$397
Omeprazole25$386
Tamsulosin Hcl28$367
Pioglitazone Hcl24$356
Gabapentin17$289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$23$23,09814 claims
Novo NordiskOzempic$983$21,83620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →